SomaLogic announces new collaboration with Janssen Research & Development
SomaLogic, Inc. has announced that it has entered into a collaborative agreement with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the agreement terms, SomaLogic will analyze ~5000 proteins in each of at least 15,000 clinical samples from Janssen to identify and validate protein biomarkers for use by Janssen and SomaLogic in predicting, diagnosing, monitoring, and treating disease. Samples will come from patients suffering from different diseases for which Janssen is developing drugs, including but not limited to rheumatoid arthritis, inflammatory bowel disease, lupus, and cardiovascular and metabolic conditions.
“We are happy that the Janssen research teams are exploring the potential of our protein-measurement platform for their drug discovery and development efforts,” said Roy Smythe, SomaLogic CEO. “We prefer this kind of ‘win-win’ collaboration, where each party shares data and expertise with the other in an effort to achieve the high value goal of more rapidly advancing healthcare.”
This agreement is part of the SomaLogic “SOMAscan® Access Program,” which was recently developed to give leading biopharmaceutical companies a way to use SomaLogic proprietary technology for their own drug discovery and development purposes, while supporting the SomaLogic mission to provide meaningful and actionable precision health information based on protein measurements across a wide range of diseases and conditions.
Specific details of the agreement were not disclosed.